An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5, Comirnaty JN.1 and Comirnaty KP.2 may be administered concomitantly with a pneumococcal conjugated vaccine (PCV). an unadjuvanted ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

Pfizer (PFE -1.64%) and BioNTech (BNTX -1.15%) recently fell behind in their race with Moderna (MRNA -1.60%) to develop new combination shots that could be worth billions in annual sales.

The vaccine combination pairs an experimental mRNA-based influenza vaccine candidate with Comirnaty, the FDA-approved Pfizer and BioNTech mRNA Covid-19 vaccine. The Phase 3 study enrolled more ...

In November, American pharmaceutical giant Pfizer and its German partner BioNTech began enrolling child volunteers aged 12 to 17 in the Phase 2/3 trials of their two-dose COVID-19 vaccine. Now ...

Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals ...